Activated fibroblasts are associated with many different tumors. Myofibroblasts, activated fibroblasts, and perivascular mesenchymal cells such as pericytes play a role in cancer progression. Many studies suggest that myofibroblasts facilitate tumor growth and cancer progression. The source for myofibroblasts and other activated fibroblasts within the tumors is still debated. Although de novo activation of quiescent fibroblasts into A-smooth muscle actin (ASMA)-positive myofibroblasts is one likely source, epithelial to mesenchymal transition and bone marrow recruitment are also evolving as possible mechanisms for the emergence of a heterogeneous population of carcinoma-associated fibroblasts. Here, we show that transforming growth factor-B1 could induce proliferating endothelial cells to undergo a phenotypic conversion into fibroblast-like cells. Such endothelial to mesenchymal transition (EndMT) is associated with the emergence of mesenchymal marker fibroblast-specific protein-1 (FSP1) and down-regulation of CD31/PECAM. Additionally, we show EndMT in tumors using the B16F10 melanoma model and the Rip-Tag2 spontaneous pancreatic carcinoma model. Crossing Tie2-Cre mice with R26Rosa-loxStop-lox-LacZ mice allows for irreversible tagging of endothelial cells. We provide unequivocal evidence for EndMT at the invasive front of the tumors in these transgenic mice. Collectively, our results show that EndMT is a unique mechanism for the accumulation of carcinoma-associated fibroblasts and suggest that antiangiogenic treatment of tumors may have a direct effect in decreasing activated fibroblasts that likely facilitate cancer progression. [Cancer Res 2007;67(21):10123-8] 
Introduction
Cancer research has traditionally focused on the alterations within genetically transformed cancer cells. In recent years, however, tumors have been increasingly perceived as complicated unorganized organs that, in addition to the cancer cells, also contain various stroma cells, such as endothelial cells, immune cells, and fibroblasts (1) (2) (3) . In fact, in some carcinomas, >90% of the tumor consists of the stroma (4, 5) . Stromal cells influence many aspects of tumor development including inception, growth, angiogenesis, local invasion, and metastasis (1, 2) .
Although it is widely accepted that fibroblasts facilitate tumor progression, the origin(s) of such activated fibroblasts are largely unknown. Activated fibroblasts likely arise from several sources. Activation and proliferation of resident tissue fibroblasts contribute to fibroblast accumulation in the tumor microenvironment (1) . Recent studies also point to a possible origin of carcinomaassociated fibroblasts (CAF) from the bone marrow. Moreover, periadventitial cells (including pericytes and vascular smooth muscle cells) are implicated as sources of activated fibroblasts (1) .
Here, we explore a hypothesis that proliferating endothelial cells might contribute to CAF via endothelial to mesenchymal transition (EndMT). We show that in two different mouse models of carcinogenesis, EndMT contributes to the appearance of CAF. We further show that primary mouse endothelial cells acquire a fibroblast-like phenotype upon exposure to transforming growth factor-h1 (TGF-h1). Furthermore, we provide evidence that tumors in endothelial cell-specific LacZ reporter mice contain fibroblasts that are also LacZ + . These results suggest that EndMT is also a source for the emergence of CAF in the tumor microenvironment.
Materials and Methods
Mice. C57BL/6 mice were from The Jackson Laboratory. Rip1-Tag2 mice were obtained from the National Cancer Institute Mouse Repository. Starting at 12 weeks of age, all RIP1-Tag2 mice received 50% sugar in their food (Harlan Teklad) to counteract hypoglycemia induced by the insulinsecreting tumors. Tie2Cre and R26Rosa-lox-Stop-lox-LacZ alleles were described previously (6, 7) . The LacZ is designed to express under the control of the ROSA promoter. In the Tie2Cre;R26Rosa-lox-Stop-lox-LacZ double transgenic mice, the stop codon at the start of the lacZ coding sequence is deleted by Cre recombinase. Tie2Cre mice express the Cre recombinase in endothelial cells, therefore, the lacZ gene is also expressed in endothelial cells. To obtain Tie2Cre;R26Rosa-lox-Stop-lox-LacZ mice, matings were set-up between Tie2 Cre-positive and homozygous R26Rosa-lox-Stop-lox-LacZ mice. These mice exhibit normal phenotypes and life spans. All mice were housed under standard conditions in the animal facility of the Beth Israel Deaconess Medical Center, Boston, MA. All experiments were conducted with the approval of the Institutional Animal Care and Use Committee of the Beth Israel Deaconess Medical Center.
Tumor studies. B16F10 cells were grown at 37jC in 5% CO 2 in DMEM with 10% heat-inactivated fetal bovine serum (FBS) and 5 ng/mL of plasmocin under sterile tissue culture conditions. The backs of C57BL/6 mice were shaved and B16F10 cells were injected s.c. on the backs of the mice (1 Â 10 6 cells/mouse). The tumors were measured using Vernier calipers, and the volume was calculated using a standard formula (width 2 Â length Â 0.52; ref. 8) . Tumors were harvested when they reached f1,000 mm 3 . The B16F10 melanoma model was used due to the expression of melanin in cancer cells. This provides an additional method to distinguish cancer cells from tumor-associated stromal cells.
Isolation of primary mouse lung endothelial cells. Mouse lung endothelial cells (MLEC) were isolated from 12-week-old wild-type C57BL/6 mice as described in our previous publications (9) . Briefly, intracellular adhesion molecule-2 expressing MLEC were enriched using rat anti-mouse intracellular adhesion (molecule-2; PharMingen) conjugated to magnetic beads (Dynabeads M-450; Dynal). MLEC were maintained in 40% Ham's Figure 1 . A, B16F10 subcutaneous tumors in C57BL/6 mice. B16F10 cancer cells were implanted s.c. into C57BL/6 mice. B16F10 tumors were analyzed when they reached a size of 800 to 1,000 mg. Left, a representative photomicrograph of an MTS-stained tumor section (original magnification, Â1.25). Right, inset from left (original magnification, Â40). Corresponding areas were analyzed by immunofluorescence labeling as displayed below. B, FSP1-CD31 and aSMA-CD31 double-labeling of B16F10 tumors. Confocal microscopy of cryosections double-labeled with antibodies to CD31 (red, left) and FSP1 (green, left) and to CD31 (red, right ) and aSMA (green, right ). TOPRO-3 was used for labeling of nuclei (blue ). In addition to the single-color panels, the pictures were merged (bottom right ). Arrows, cells which were labeled positive for both FSP1 and CD31 (yellow, left ) or both aSMA and CD31 (right ). Original magnification, Â100. F-12, 40% DME-low glucose, 20% FBS supplemented with heparin, endothelial mitogen (Biomedical Technologies, Inc.), glutamine, and penicillin/ streptomycin. MLEC were characterized for homogeneity by morphologic observations and by immunofluorescence staining for endothelial-specific markers as previously described (9) . Cells between passages 3 and 6 were used for the experiments.
In vitro induction of EndMT. Primary MLECs (1 Â 10 6 /dish) were cultured in 40% Ham's F-12, 40% DME-low glucose, 2% FBS supplemented with heparin, glutamine, and penicillin/streptomycin once they had adhered. In order to induce EndMT, the medium was supplemented with 10 ng/mL of TGF-h1.
Immunocytochemistry. EndMT in MLEC was visualized by immunofluorescent double staining with antibodies to CD31, a-smooth muscle actin (aSMA), and fibroblast-specific protein-1 (FSP1) as described with minor modifications (10) . Cells were fixed with acetone and incubated overnight at 4jC with the primary antibodies. Cells were then washed again and incubated for 45 min at room temperature with Alexa Fluor 488-and 568-conjugated secondary antibodies (Invitrogen). The cells were covered using Vectashield mounting media (Vector). Staining was analyzed using a confocal microscope.
Immunohistochemistry. We did immunohistochemistry as previously described (11) . Frozen tissue was cut into 5-Am-thick cross-sections which were fixed in 100% acetone at À20jC for 10 min. We incubated the sections with primary antibodies at 4jC overnight. The primary antibodies were rat anti-CD31 (clone MEC13.3; BD PharMingen), mouse anti-aSMA (clone 1A4; Sigma), rabbit anti-FSP1 (polyclonal, research gift from Eric G. Neilson, Vanderbilt University, Nashville, TN), rabbit anti-h-galactosidase (polyclonal; Cappel), mouse anti-FSP1 (clone 1F12-1G7; Novus Biologicals). For detection of primary antibodies raised in rabbit or rat, we used Alexa Fluor 488-and 568-conjugated secondary antibodies (Invitrogen). Primary antibodies raised in mice were detected using the M.O.M. kit (Vector Laboratories). After the sections were washed with TBS, they were subsequently stained with secondary antibodies. The nuclei were counterstained with 4 ¶,6-diamidino-2-phenylindole (Vectashield) for fluorescence microscopy or with TOPRO-3 (Molecular Probes) for confocal microscopy. FSP-1 antibody was a gift from E.G. Neilson. Staining was analyzed using a Zeiss LSM 510 Meta scanning confocal microscope. Ten visual fields per tumor and three size-matched (f1,000 mm 3 ) tumors were analyzed for colocalization of endothelial and fibroblast markers.
LacZ staining. Frozen tissue was cut into 5-Am-thick cross-sections which were fixed in 4% paraformaldehyde at 4jC for 10 min. Sections were then washed thrice in PBS and then incubated at 37jC in 1 mg/mL of X-Gal (Sigma), 5 mmol/L of potassium ferrocyanide, 5 mmol/L of potassium ferricyanide, 2 mmol/L of MgCl 2 , 0.2% NP40, and 0.1% sodium-deoxycholate in PBS for 72 h as described (12) .
Statistical analysis. Descriptive analysis was done using SigmaStat software. Results are expressed as means F SE.
Results

FSP1
+ CD31 + and ASMA + CD31 + double-positive cells in B16F10 mouse melanomas. Previous studies show that EndMT contributes to the accumulation of fibroblasts in the setting of heart fibrosis, similar to EndMT which occurs during heart development (13) . Here, we test the hypothesis that a portion of the fibroblasts present in the tumors could derive from endothelial cells via EndMT. We analyzed B16F10 mouse melanomas (Fig. 1A) and we did labeling experiments using antibodies to CD31 (endothelial cell marker; red) and the fibroblast markers FSP1 (green) and aSMA (green). Confocal microscopy reveals colocalization of both FSP1 and CD31 as well as of aSMA and CD31 (Fig. 1B) . Approximately 11% of the aSMA + cells in the tumor microenvironment are doublepositive for both aSMA and CD31. Among the FSP1 + perivascular cells in the tumor periphery, f40% were also labeled positive for CD31, suggesting that these cells represent a class of CAFs that also express endothelial markers (Fig. 1C and D) .
LacZ and FSP1 double-positive cells in the tumor stroma of Tie2-cre;R26Rosa-lox-Stop-lox-LacZ transgenic mice. FSP1/ CD31 and aSMA/CD31 double-labeling experiments using antibodies allow for the identification of intermediate stages of EndMT, but not for cells of endothelial cell origin that have lost their endothelial cell markers. Therefore, we did studies using implanted s.c. B16F10 tumors in Tie2-cre;R26Rosa-lox-Stop-lox-LacZ transgenic mice. In these mice, Tie2-cre-positive endothelial cells were irreversibly tagged with an expression of the LacZ transgene ( Fig. 2A) . Tumors of 1,000 mm 3 size were harvested and enzymatic h-galactosidase reaction was done in these tumors. LacZ-positive cells were marked by a blue precipitate in this assay. In addition to blue cells within vessels (endothelial cells), single blue cells were also found scattered throughout the tumor stroma (Fig. 2B, black  arrows) . To further identify the origin of such cells, we did doublelabeling experiments using antibodies to h-galactosidase (red), FSP1 (green), and aSMA (green). The tissue was analyzed using (Fig. 2C and D) . Approximately 30% of the FSP1 + cells in the tumor stroma were h-gal and FSP1 doublepositive and 12% of the aSMA + cells revealed double positivity for aSMA and h-gal (Fig. 2C and D) . Collectively, our studies provide a compelling genetic evidence for EndMT-derived CAF in the tumor microenvironment.
TGF-B1 induces EndMT in primary MLECs. TGF-h1 is a potent inducer of epithelial to mesenchymal transitions (14, 15) . To further establish EndMT, we cultured and exposed primary MLECs to TGF-h1. Exposure to 10 ng/mL of TGF-h1 causes MLEC to acquire a spindle-shaped fibroblast-like morphology (Fig. 3A) . Such phenotypic transitions are associated with a dramatic decrease in CD31 expression and an increase in FSP1 protein expression (Fig. 3B) . Analysis of B16F10 tumor tissue with antibodies to FSP1 (red) and TGF-h1 (green) shows an accumulation of FSP1 + cells in areas with the most intense TGF-h1 labeling (Fig. 3C) , further providing causal support to the notion that TGF-h1 mediates EndMT within the tumor microenvironment.
Evidence for EndMT in the Rip1-Tag2 multistage carcinoma model. We used Rip1-Tag2 transgenic mice as a second tumor model to gain further insights into the occurrence of EndMT within the tumor microenvironment. In Rip1-Tag2 transgenic mice, the large T-antigen of SV40 is exclusively expressed in the h-cells of the excretory pancreas (16) . In this cancer model, every mouse developed pancreatic islet tumors by 12 to 14 weeks of age (17) . We harvested tumors from RIP1-Tag2 transgenic mice at the age of 13.5 weeks (advanced tumor burden; Fig. 4A ) and did doublelabeling experiments using antibodies to FSP1 and CD31 (Fig. 4B  and C) . Similar to B16F10 tumors, double-labeling experiments revealed a significant portion of FSP1 + cells positive for both FSP1 and CD31, indicating EndMT as a mechanism for the recruitment of CAFs (Fig. 4D) . Immunofluorescence labeling using primary antibodies to TGF-h1 confirmed the presence of TGF-h1 within the pancreatic islet tumor microenvironment (Fig. 4E) .
Discussion
Solid tumors are a composite of cancer cells, endothelial cells, inflammatory cells, and fibroblasts (2) . Although the relevance of fibroblasts in cancer progression is increasingly being recognized, little is known about their origin (1) . In this study, we provide evidence that endothelial cells contribute to the pool of CAFs via EndMT. Our previous studies have shown that CAF are a heterogeneous population (18) . In this study, we use two different tumor models, in vitro EndMT assay and Tie2-cre;R26Rosa-loxStop-lox-LacZ transgenic mice, and we provide evidence that endothelial cells contribute to the accumulation of fibroblasts within the tumor microenvironment of angiogenic tumors. Our study also supports the notion that not all CAF are aSMA-positive and that FSP1 + fibroblasts constitute a separate class of activated fibroblasts in the tumor microenvironment (18) . The origin of activated fibroblasts and myofibroblasts is not exclusively via EndMT. Interestingly, fewer cells in our study colocalize with aSMA and CD31/LacZ compared with FSP1 and CD31/LacZ. Future studies will hopefully analyze many different mouse and human tumors to ascertain whether EndMT is a universal process in many cancers.
Several studies have shown the capacity of TGF-h1 in mediating epithelial to mesenchymal transition (11, 15) . Cardiac endothelial cells undergo EndMT when exposed to TGF-h1, and cardiac fibrosis is associated with EndMT (13) . In the present study, we show that TGF-h1-exposed lung endothelial cells could undergo EndMT. We propose that endothelial cells under the influence of autocrine and paracrine TGF-h1 (abundantly present in many tumors; refs. 19, 20) , undergo EndMT. Our use of tumors grown in Tie2-cre;R26Rosa-lox-Stop-lox-LacZ transgenic mice provides compelling proof that endothelial cells are capable of acquiring mesenchymal transition. Collectively, our study provides evidence that EndMT is an important source for the accumulation of cancerpromoting CAFs.
